- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Xetra | 86,740 | 14.06.24 17:35:44 | -1,810 | -2,04% | 0,000 | 0,000 | 88,320 | 86,740 |
|
Regeneron Pharmaceuticals | 881535 | NASDAQ | 1.036,520 | 14.06.24 22:50:55 | +9,970 | +0,97% | 1.036,870 | 1.046,000 | 1.024,300 | 1.036,520 |
